Bristol-Myers Squibb BMY releases its next round of earnings this Thursday, Jan. 24. Here's Benzinga's essential guide to Bristol-Myers Squibb's Q4 earnings report.
Earnings and Revenue
Wall Street analysts see Bristol-Myers Squibb reporting earnings of 85 cents per share on sales of $5.99 billion.
In the same quarter last year, Bristol-Myers Squibb posted EPS of 68 cents on sales of $5.45 billion. If the company were to report inline earnings when it publishes results, earnings would be up 25.00 percent. Sales would be up 9.93 percent on a year-over-year basis. Bristol-Myers Squibb's reported EPS has stacked up against analyst estimates in the past like this:
| Quarter | Q3 2018 | Q2 2018 | Q1 2018 | Q4 2017 |
| EPS Estimate | 0.91 | 0.88 | 0.83 | 0.67 |
| EPS Actual | 1.09 | 1.01 | 0.94 | 0.68 |
Stock Performance
Over the last 52-week period, shares are down 20.17 percent. Given that these returns are generally negative, long-term shareholders are probably a little upset going into this earnings release. Analysts have adjusted their estimates higher for EPS and revenues over the past 90 days. The most common rating by analysts on Bristol-Myers Squibb stock is a Neutral. The strength of this rating has maintained conviction over the past three months.
Conference Call
Bristol-Myers Squibb's Q4 conference call is scheduled to begin at 10:30 a.m. ET and can be accessed here: https://event.on24.com/wcc/r/1868013/41E2C4F8CF3E6AC564098D206ECDC05B
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
